Form 4: Ultragenyx Director Receives Equity Compensation

Director Matthew K. Fust acquired 7,751 restricted stock units and 14,058 stock options as part of annual compensation.

Summary

• Director Matthew K. Fust was granted 7,751 Restricted Stock Units (RSUs) on May 14, 2026.
• Director Matthew K. Fust was granted 14,058 stock options with an exercise price of $25.80.
• Both the RSUs and stock options vest on the earlier of the next Annual Meeting of Stockholders or May 14, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.

Positives

• Equity grants align director interests with long-term shareholder value.
• Standard compensation practice for non-employee directors.

Negatives

• Issuance of equity results in minor dilution to existing shareholders.

Risks

• Potential for future dilution if additional equity-based compensation plans are implemented.

Future Outlook

The equity grants are subject to vesting conditions tied to the next Annual Meeting of Stockholders or May 14, 2027.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation common in the biotechnology sector, reflecting standard corporate governance practices for board members.

Comparison to Industry Standards

• The grant of RSUs and options to non-employee directors is consistent with standard compensation packages for mid-cap biotechnology companies.
• Vesting schedules tied to annual meetings are standard practice for board members in the U.S. public market.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity awards on the earlier of the next Annual Meeting or May 14, 2027.

Key Dates

Keywords

Ultragenyx, RARE, Form 4, Director Compensation, Equity Grant, Insider Transaction